Cargando…

Asparaginase-Phage P22 Nanoreactors: Toward a Biobetter Development for Acute Lymphoblastic Leukemia Treatment

Asparaginase (ASNase) is a biopharmaceutical for Acute Lymphoblastic Leukemia (ALL) treatment. However, it shows undesirable side effects such as short lifetimes, susceptibility to proteases, and immunogenicity. Here, ASNase encapsidation was genetically directed in bacteriophage P22-based virus-lik...

Descripción completa

Detalles Bibliográficos
Autores principales:	Díaz-Barriga, Cristina, Villanueva-Flores, Francisca, Quester, Katrin, Zárate-Romero, Andrés, Cadena-Nava, Ruben Dario, Huerta-Saquero, Alejandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170886/ https://www.ncbi.nlm.nih.gov/pubmed/33922106 http://dx.doi.org/10.3390/pharmaceutics13050604

Ejemplares similares

Encapsulation of Asparaginase as a Promising Strategy to Improve In Vivo Drug Performance
por: Villanueva-Flores, Francisca, et al.
Publicado: (2021)

A Novel Formulation of Asparaginase Encapsulated into Virus-like Particles of Brome Mosaic Virus: In Vitro and In Vivo Evidence
por: Villanueva-Flores, Francisca, et al.
Publicado: (2023)

Rhizobium etli asparaginase II: An alternative for acute lymphoblastic leukemia (ALL) treatment
por: Huerta-Saquero, Alejandro, et al.
Publicado: (2013)

Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles
por: Brumano, Larissa Pereira, et al.
Publicado: (2019)

Future of anti-VEGF: biosimilars and biobetters
por: Kapur, Monika, et al.
Publicado: (2022)

Identification of L-asparaginases from Streptomyces strains with competitive activity and immunogenic profiles: a bioinformatic approach
por: González-Torres, Iván, et al.
Publicado: (2020)

Biosimilar, biobetter and next generation therapeutic antibodies
Publicado: (2011)

Biobetters From an Integrated Computational/Experimental Approach
por: Kuyucak, Serdar, et al.
Publicado: (2017)

From Biologics to Biosimilars and Biobetters – Democratization of High-end Therapeutics
por: Honavar, Santosh G
Publicado: (2021)

Pharmacogenetics of asparaginase in acute lymphoblastic leukemia
por: Abaji, Rachid, et al.
Publicado: (2019)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

An Omalizumab Biobetter Antibody With Improved Stability and Efficacy for the Treatment of Allergic Diseases
por: Liu, Peipei, et al.
Publicado: (2020)

Subcutaneous Infliximab in Refractory Crohn’s Disease Patients: A Possible Biobetter?
por: Cerna, Karin, et al.
Publicado: (2023)

Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
por: Strohl, William R.
Publicado: (2015)

Targeted Enzymatic VLP‐Nanoreactors with β‐Glucocerebrosidase Activity as Potential Enzyme Replacement Therapy for Gaucher's Disease
por: Chauhan, Kanchan, et al.
Publicado: (2022)

L-Asparaginase induced thrombosis in acute lymphoblastic leukemia
por: Kulkarni, Ketan P.
Publicado: (2012)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

L-asparaginase in the treatment of patients with acute lymphoblastic leukemia
por: Egler, Rachel A., et al.
Publicado: (2016)

Acute pancreatitis following L-asparaginase in acute lymphoblastic leukemia
por: M'harzi, Soulaimane, et al.
Publicado: (2022)

Our Experiences with Asparaginase Activity Measurements in Children with Lymphoblastic Diseases
por: Müller, Judit, et al.
Publicado: (2023)

Acute Pancreatitis and Diabetic Ketoacidosis following L-Asparaginase/Prednisone Therapy in Acute Lymphoblastic Leukemia
por: Quintanilla-Flores, Dania Lizet, et al.
Publicado: (2014)

PEG-asparaginase and native Escherichia coli L-asparaginase in acute lymphoblastic leukemia in children and adolescents: a systematic review
por: Medawar, Camile Valle, et al.
Publicado: (2020)

Multifunctionalized biocatalytic P22 nanoreactor for combinatory treatment of ER+ breast cancer
por: Chauhan, Kanchan, et al.
Publicado: (2018)

Nanoreactors for green catalysis
por: De Martino, M Teresa, et al.
Publicado: (2018)

Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli‐Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia
por: Vrooman, Lynda M., et al.
Publicado: (2015)

Asparaginase (native ASNase or pegylated ASNase) in the treatment of acute lymphoblastic leukemia
por: Avramis, Vassilios I, et al.
Publicado: (2006)

L-asparaginase-induced Parotitis in an Elderly Patient with Acute Lymphoblastic Leukemia
por: Saburi, Masuho, et al.
Publicado: (2020)

L-Asparaginase Toxicity in the Treatment of Children and Adolescents with Acute Lymphoblastic Leukemia
por: Schmidt, Madalina-Petronela, et al.
Publicado: (2021)

PB1739: ADVERSE EFFECTS OF ASPARAGINASE IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA
por: Chenbah, Wafa, et al.
Publicado: (2023)

Application of Lectin Array Technology for Biobetter Characterization: Its Correlation with FcγRIII Binding and ADCC
por: Roucka, Markus, et al.
Publicado: (2016)

Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters
por: Kim, HoUng, et al.
Publicado: (2021)

Efficacy and safety of PEG-asparaginase versus E. coli L-asparaginase in Chinese children with acute lymphoblastic leukemia: a meta-analysis
por: Dai, Zhan-Jing, et al.
Publicado: (2021)

A Review of L-Asparaginase Hypersensitivity in Paediatric Acute Lymphoblastic Leukaemia Patients with Regard to the Measurement of Anti-Asparaginase Antibodies and Their Genetic Predisposition
por: Tan, Yan Qi, et al.
Publicado: (2023)

Update on the Use of l-Asparaginase in Infants and Adolescent Patients with Acute Lymphoblastic Leukemia
por: Andrade, Augusto F, et al.
Publicado: (2014)

Mechanisms of cell death induced by arginase and asparaginase in precursor B-cell lymphoblasts
por: Métayer, Lucy E., et al.
Publicado: (2018)

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017)

Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy
por: Juluri, Krishna R, et al.
Publicado: (2022)

Is asparaginase encapsulated in erythrocytes effective as second‐line treatment in acute lymphoblastic leukaemia?
por: van der Sluis, Inge M., et al.
Publicado: (2022)

Tip-induced nanoreactor for silicate
por: Gao, Ming, et al.
Publicado: (2015)

P22-Based Nanovaccines against Enterohemorrhagic Escherichia coli
por: Huerta-Saquero, Alejandro, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ig4soo1hbe4u0oipeabc3gh8jn